Zydus Wins First Generic Climara Pro Approval; Corium's Identical-Strength BE Study Compresses the Exclusivity Window

FDA Approves First Generic Once-Weekly Hormone Therapy Patch

The U.S. Food and Drug Administration (FDA) has approved the first generic version of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a once-weekly transdermal hormone therapy patch. Approved on October 20, 2026, this generic, manufactured by Zydus Pharmaceuticals (USA) Inc., is indicated for women with an intact uterus to treat moderate to severe vasomotor symptoms due to menopause and prevent postmenopausal osteoporosis. This approval aims to increase access to affordable, high-quality medications, aligning with the FDA's commitment to public health.

• Enhanced Accessibility and Affordability: The approval of the first generic estradiol and levonorgestrel transdermal system by Zydus Pharmaceuticals (USA) Inc. is a significant step towards making effective hormone therapy more accessible and affordable for women. This aligns with the FDA’s Public Health Pillar focused on increasing access to affordable medicines, as generic drugs account for nine out of ten prescriptions filled in the U.S.
• Convenient Once-Weekly Dosing: The generic transdermal system offers a convenient once-weekly application, providing an alternative to daily oral medications. This dosing regimen is expected to improve patient adherence and management of care for women with an intact uterus, who require both estrogen and progestogen to reduce the risk of endometrial hyperplasia associated with estrogen-only treatments.
• Specific Indications and Safety Profile: The approved generic is therapeutically equivalent to Climara Pro, indicated for treating moderate to severe vasomotor symptoms due to menopause and preventing postmenopausal osteoporosis in women with an intact uterus. It carries contraindications including breast cancer, DVT/PE, and hepatic impairment, with common adverse reactions such as application site reactions, vaginal bleeding, and breast pain.

Expanding Access: The Evolving Menopause Treatment Landscape

The most consequential development in the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause has been the clinical validation and regulatory approval of neurokinin receptor antagonists, which target the KNDy (kisspeptin, neurokinin B, dynorphin) neuronal pathway in the hypothalamus. Estrogen withdrawal during menopause leads to hyperactivation of neurokinin B signaling, and the identification of the NK3 receptor as a key mediator of hot flashes drove the development of this drug class. Fezolinetant, a selective NK3 receptor antagonist, received FDA approval on 12 May 2023, becoming the first non-hormonal, mechanism-targeted therapy for this indication. Its approval was supported by the SKYLIGHT 1, 2, and 4 phase 3 trials, with a pooled safety analysis across all three 52-week studies (totalling 952 placebo, 1,103 fezolinetant 30 mg, and 1,100 fezolinetant 45 mg participants) confirming treatment-emergent adverse event rates of 55.3%, 62.9%, and 65.4%, respectively, endometrial safety results within FDA criteria, and no cases meeting Hy's law criteria for severe drug-induced liver injury. The MOONLIGHT 3 open-label trial further extended these findings to Chinese women, demonstrating that fezolinetant 30 mg once daily was generally safe and well tolerated over 52 weeks, with no clinically relevant change in endometrial thickness (baseline 2.95 ± 1.11 mm; week 52, 2.94 ± 1.18 mm).

Elinzanetant, a dual NK-1/NK-3 receptor antagonist, has emerged as a second agent in this class with a differentiated pharmacological profile. The OASIS 1 and 2 phase 3 trials demonstrated that elinzanetant 120 mg once daily significantly reduced VMS frequency at week 4 (OASIS 1: −3.3 [95% CI, −4.5 to −2.1], P < .001; OASIS 2: −3.0 [95% CI, −4.4 to −1.7], P < .001) and week 12 (OASIS 1: −3.2 [95% CI, −4.8 to −1.6], P < .001; OASIS 2: −3.2 [95% CI, −4.6 to −1.9], P < .001), alongside improvements in VMS severity, sleep disturbance, and menopause-related quality of life. The NIRVANA phase 2 study further characterised elinzanetant's effect on objective sleep using polysomnography, estimating a reduction in wakefulness after sleep onset at week 4 versus placebo (least square mean difference = −22.50 minutes, 90% CI: −35.47, −9.52). A comprehensive liver safety analysis across 24 phase 1, three phase 2, and four phase 3 studies found no imbalance between elinzanetant and placebo in ALT elevations, no Hy's law cases, and no cholestatic injury, leading the liver safety monitoring board to consider liver test monitoring unnecessary in clinical practice — a meaningful differentiation from fezolinetant, whose labelling includes liver monitoring requirements. A network meta-analysis comparing elinzanetant with other non-hormonal therapies found that elinzanetant significantly improved sleep disturbance (PROMIS SD-SF-8b) score versus fezolinetant (mean difference: −2.67 [−3.92, −1.42]), though a matching-adjusted indirect comparison of the SKYLIGHT-1/2 and OASIS-1/2 trial populations found that fezolinetant and elinzanetant had comparable efficacy in reducing VMS frequency and severity, and that differences in sleep disturbance reduction did not translate into a significant difference in overall quality of life as measured by MENQOL.

Beyond head-to-head comparisons within the NK receptor antagonist class, the broader treatment landscape has been reshaped by growing evidence supporting non-hormonal options for populations who cannot or choose not to use hormone therapy. The DAYLIGHT phase 3b study specifically enrolled women considered unsuitable for hormone therapy — including those with contraindications, cautions, prior stoppers, and those averse to its use — and demonstrated statistically significant reductions in VMS frequency and severity with fezolinetant 45 mg versus placebo at week 24, alongside improvements in PROMIS SD SF 8b total score (least squares mean difference: −2.5; 95% CI: −3.9, −1.1; P < .001), MENQOL total score (LS mean difference: −0.44; 95% CI: −0.69, −0.18; P < .001), and multiple WPAI-VMS domains. Real-world uptake data from a retrospective cohort of 9,853 women prescribed fezolinetant between May 2023 and December 2024 — including 2,022 (20.5%) with a breast cancer diagnosis and 1,315 (13.3%) over age 65 — underscores both the breadth of the population seeking non-hormonal options and the need for postmarketing safety studies in subgroups excluded from the pivotal trials. Systematic reviews and meta-analyses have reinforced the high certainty of evidence supporting both fezolinetant and elinzanetant, with the meta-analytic estimate for elinzanetant 120 mg showing a mean difference in VMS frequency reduction of 2.99 (95% CI, 1.74–4.23, I² = 0%) and a significant improvement in sleep quality (mean difference 4.65; 95% CI, 3.73–5.56, I² = 0%), positioning neurokinin receptor antagonists as a clinically validated, mechanism-targeted alternative to hormone therapy for moderate-to-severe menopausal VMS.

Addressing Unmet Needs in Menopause Management

Managing moderate-to-severe vasomotor symptoms (VMS) associated with menopause remains a complex clinical challenge, with no single treatment offering universal applicability, optimal efficacy, and a fully favorable safety profile. The therapeutic landscape spans hormonal and non-hormonal options, each carrying distinct limitations that constrain their use across diverse patient populations.

• Hormonal therapy (HT) carries well-characterized risks that restrict its use. Conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA) are associated with approximately 1 excess event per 1,000 person-years for stroke, venous thromboembolism, and breast cancer (with CEE plus MPA). Oral HT is specifically associated with increased risk of venous thromboembolism, gallbladder disease, and possibly stroke — risks that can be mitigated by transdermal estradiol but not eliminated entirely. HT is contraindicated or avoided in women with hormone receptor-positive breast cancer receiving adjuvant endocrine therapy, a population with a high prevalence of treatment-induced VMS (hot flash prevalence ranging from 32.5% to 82.9% in observational studies).

• Non-hormonal pharmacological options demonstrate meaningful but inferior efficacy compared to estrogen. SSRIs/SNRIs achieve approximately 40%–60% efficacy for VMS reduction. In a head-to-head randomized trial, low-dose venlafaxine 75 mg/day reduced VMS frequency by 47.6% versus 52.9% for low-dose estradiol 0.5 mg/day, with the difference of 0.6 fewer VMS per day not reaching statistical significance (P = 0.09) but remaining of uncertain clinical relevance. Paroxetine 7.5 mg has been associated with a 33%–67% reduction in hot flash frequency versus 13.7%–37.8% with placebo. Gabapentin reduces hot flash frequency and composite scores significantly versus placebo, but is associated with higher dropout rates due to adverse events, with dizziness/unsteadiness (RR = 6.94) and fatigue/somnolence (RR = 4.78) occurring significantly more frequently than with placebo.

• Newer NK3 receptor antagonists address some gaps but introduce hepatotoxicity monitoring requirements. Fezolinetant 45 mg demonstrated significantly greater VMS frequency reduction than all non-hormonal therapies evaluated in network meta-analysis, including paroxetine 7.5 mg (mean difference 1.66 [95% CrI 0.63–2.71]) and gabapentin ER 1800 mg (mean difference 1.63 [95% CrI 0.48–2.81]). However, its labeling includes recommendations for liver function monitoring — required at baseline and regularly thereafter (monthly for the first 3 months and at 6 and 9 months) — due to observed transaminase elevations, including in a phase 2b study where nine participants experienced elevations exceeding 3× the upper limit of normal.

• Breast cancer survivors represent a population with particularly limited and evidence-poor treatment options. Evidence gaps for treatment-induced VMS in individuals receiving tamoxifen or aromatase inhibitors include economic burden data and treatment management strategies. Menopausal hormone therapy is contraindicated in hormone receptor-positive breast cancer, and most evidence for non-hormonal alternatives is based on women older than 50 years with breast cancer, limiting generalizability. Elinzanetant provides the first Phase 3 evidence in the specific cohort of patients with breast cancer receiving endocrine therapy (OASIS-4), though fezolinetant's role in breast cancer survivors remains under investigation.

• Special populations and long-term data gaps persist across the treatment landscape. Women with premature ovarian insufficiency, cancer survivors, and those with cardiovascular disease or vascular risk factors require tailored strategies for which evidence remains limited. Long-term safety data gaps are acknowledged across non-hormonal options, and challenges including access inequities further constrain the translation of available therapies into clinical practice for diverse populations.

Understanding the Safety Profile of Estradiol/Levonorgestrel Patch

Published safety and tolerability data for estradiol and levonorgestrel span several clinical contexts, including contraception, menopausal hormone therapy (MHT), and endometrial protection, revealing a consistent pattern of indication-specific risks and tolerability trade-offs.

• Venous thromboembolism (VTE) risk in contraception: Combined oral contraceptives (COCs) containing levonorgestrel carry a lower VTE risk relative to other progestogens. In a national Danish cohort study, the rate ratio for VTE with levonorgestrel-containing COCs served as the reference comparator, with desogestrel (rate ratio 1.82, 95% CI 1.49–2.22), gestodene (1.86, 95% CI 1.59–2.18), drospirenone (1.64, 95% CI 1.27–2.10), and cyproterone (1.88, 95% CI 1.47–2.42) all showing significantly higher risk for the same oestrogen dose and duration of use. The MEGA case-control study similarly found levonorgestrel-containing COCs associated with an approximately fourfold increased VTE risk versus non-use (OR 3.6, 95% CI 2.9–4.6), compared with 7.3-fold for desogestrel and 6.3-fold for drospirenone. A network meta-analysis confirmed that COCs with 30–35 µg ethinylestradiol combined with gestodene, desogestrel, cyproterone acetate, or drospirenone carried approximately 50–80% higher VTE risk than levonorgestrel-containing formulations.

• Transdermal estradiol/levonorgestrel patch — bleeding and tolerability in MHT: In a systematic review of continuous-combined MHT formulations, the E2/levonorgestrel patch was associated with a cumulative amenorrhea rate of 16% over one year, among the lower rates reported across approved regimens. The review noted that oral formulations generally demonstrated a better bleeding profile than transdermal formulations overall.

• Endometrial safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) in tamoxifen users: Across four RCTs (n = 543), the 20 µg/day LNG-IUS reduced the incidence of endometrial polyps over both 12 months (Peto OR 0.22, 95% CI 0.08–0.64) and long-term follow-up of 24–60 months (Peto OR 0.22, 95% CI 0.13–0.39), and reduced endometrial hyperplasia over long-term follow-up (Peto OR 0.13, 95% CI 0.03–0.67). However, at 12 months the LNG-IUS increased abnormal vaginal bleeding or spotting compared with surveillance alone (Peto OR 7.26, 95% CI 3.37–15.66), with this excess attenuating by 24 months (Peto OR 2.72, 95% CI 1.04–7.10) and no cases reported in either group by 60 months.

• Contraceptive patch compliance and adverse events: In trials comparing the levonorgestrel plus ethinyl estradiol (EE) transdermal patch with COCs, patch users were less likely to have missed days of therapy (OR 0.36, 95% CI 0.25–0.51). Users of the levonorgestrel-containing patch also reported less vomiting, headaches, and fatigue compared with COC users, a tolerability profile distinct from the norelgestromin-containing patch, which was associated with more breast discomfort, dysmenorrhea, nausea, and vomiting.

• Long-term contraceptive continuation with the LNG-IUS: In a 5-year observational study of 356 women (parous and nulliparous), a T-shaped LNG-IUS releasing 20 µg levonorgestrel/day produced only one accidental pregnancy and two expulsions over 27,269 woman-months. Medical removals for abnormal bleeding, pain, and other reasons accounted for 12.7% of discontinuations, and no serious adverse events (perforation or pelvic inflammatory disease) were reported. The 5-year discontinuation rate was 25.7%, including women who discontinued for pregnancy wish.

• FAERS pharmacovigilance data on COC-associated thromboembolic events: A real-world analysis of the FDA Adverse Event Reporting System found that levonorgestrel-containing COCs were significantly associated with VTE. The median time-to-onset of all thromboembolic events was 264 days, with VTE onset (median 258.0 days) shorter than arterial thromboembolism onset (344.0 days), and Weibull shape parameter analysis indicated early failure-type features across all disproportionality signals.

Transdermal HRT Market Shifts with Generic Climara Pro

The recent FDA approval of a generic version of Climara Pro represents a pivotal moment for women navigating menopause. This transdermal system, which delivers both estradiol and levonorgestrel, is a cornerstone in managing the often-debilitating moderate to severe vasomotor symptoms and preventing postmenopausal osteoporosis. Research consistently demonstrates estradiol's effectiveness in alleviating hot flashes and its critical role in maintaining bone mineral density, with lower estradiol levels being linked to decreased BMD and increased fracture risk. For women with an intact uterus, the inclusion of levonorgestrel is paramount, as progestogens are essential to counteract the proliferative effects of estrogen on the endometrium, thereby mitigating the risk of endometrial hyperplasia and carcinoma.

This generic entry is poised to significantly enhance patient access to this established therapy by introducing a more affordable option, which can improve adherence and overall health outcomes. Furthermore, the transdermal delivery method itself holds strategic importance. Studies suggest that transdermal estradiol may offer a more favorable cardiovascular safety profile, including effects on heart rate variability, compared to oral estrogen formulations, potentially influencing prescribing preferences towards this route of administration.

However, several considerations remain crucial. While levonorgestrel is intended for endometrial protection, the effectiveness of its dose and delivery in fully opposing estradiol's effects warrants ongoing vigilance, as some progestogen regimens have shown to be insufficient. Additionally, while generics are generally bioequivalent, some modified-release products can exhibit variability in pharmacokinetic profiles, which could subtly affect clinical outcomes. Finally, despite the potential cardiovascular advantages of transdermal delivery, hormone therapy always requires a comprehensive assessment of individual patient risk factors, particularly given that frequent hot flashes may independently signal a vulnerable vascular phenotype. This approval, therefore, not only broadens access but also reinforces the nuanced clinical considerations inherent in menopausal hormone therapy.